Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 4, Pages 798-803
Publisher
Oxford University Press (OUP)
Online
2014-12-24
DOI
10.1093/annonc/mdu577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
- (2014) Paolo Antonio Ascierto et al. CANCER INVESTIGATION
- Targeted Therapies for Cutaneous Melanoma
- (2014) Damien Kee et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Update on the role of ipilimumab in melanoma and first data on new combination therapies
- (2013) Michele Maio et al. CURRENT OPINION IN ONCOLOGY
- MC13-0045 Genes from the TP53 network and their role in ovarian cancer prognosis and response to chemotherapy
- (2013) A. Podgorska et al. EUROPEAN JOURNAL OF CANCER
- The cost of unresectable stage III or stage IV melanoma in Italy
- (2013) Michele Maio et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
- (2012) Vafa Shahabi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
- (2012) Wenshi Wang et al. Journal of Translational Medicine
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determinants of survival in patients with brain metastases from cutaneous melanoma
- (2010) M Staudt et al. BRITISH JOURNAL OF CANCER
- Prognostic factors for survival in melanoma patients with brain metastases
- (2010) Michael A. Davies et al. CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search